

File No.- BMSIC/40030/474-2024/9306

दिनांक:-09/01/2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना
BMSICL की निविदा संख्या- BMSIC/DRUGS/24-13 से संबंधित प्राप्त ई-निविदाओं के तकनीकी
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/24-13**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 12 (बारह) ई-निविदा प्राप्त हुई। उक्त 12 (बारह) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं **e-proc 2.0 के website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 16/01/2025 के अपराह्न 05:00 बजे तक केवल **e-proc 2.0 के website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के website (www.eproc2.bihar.gov.in) के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


(हरेन्द्र राम)
महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/474-2024/9306

दिनांक:-09/01/2025

प्रतिलिपि :- प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं **e-proc2 (www.eproc2.bihar.gov.in)** पर अपलोड करना सुनिश्चित करें।


महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/24-13

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : - Unicure India Ltd. Total Number of Pages Submitted in bid documents: -1 to 154

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	Yes	15	Yes	-
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	25-29	Yes	AS Per Bid Document clause 3(b) BG Submitted for EMD must be schedule/Nationalized Bank Payable at Patna But firm has not submitted the same. (Kindly use New Address of BMSICL IN Bank Gaurantee)
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	77-112	Yes	-
4	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	39-48	Yes	-
5	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	19-21	Yes	-
6	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	23	Yes	-
7	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	31-36	Yes	-

Anuradha

Bhaskar

124

TENDER NO. BMSIC/DRUGS/24-13

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Unicare India Ltd. Total Number of Pages Submitted in bid documents:- 154

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	51-52	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	4-5	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	117-144	No	(i) Form- 25 B (License no. 01/RPL of 1991) and their last retention certificate form 26 B not submitted. (ii) Pack size of quoted product NIT sl. No. 7 is not as per NIT. (iii) Product approval is less than three year i.e. 25.07.2024 of NIT sl. No. 10.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	117-144	No	(iv) Product approval is controlled release tablet which is not as per NIT sl. no. 22. (v) Product approval is not as sublingual tablet which is not as per NIT sl. no. 24. (vi) Product approval is Gastro resistant tablet which is not as per NIT sl. no. 34.
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	59--76	No	MSC not submitted for quoted product of NIT sl. No. 14, 24, 25, 26, 29, 34, 38 & 43.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

20/1/25






03/01/2025

03/01/25

3/1/25

123

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	145-153	Yes	
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	117-144	No	<p>(i) Form- 25 B (License no. 01/RPL of 1991) and their last retention certificate form 26 B not submitted.</p> <p>(ii) Pack size of quoted product NIT sl. No. 7 is not as per NIT.</p> <p>(iii) Product approval is less than three year i.e. 25.07.2024 of NIT sl. No. 10.</p> <p>(iv) Product approval is controlled release tablet which is not as per NIT sl. no. 22.</p> <p>(v) Product approval is not as sublingual tablet which is not as per NIT sl. no. 24.</p> <p>(vi) Product approval is Gastro resistant tablet which is not as per NIT sl. no. 34.</p>
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	NA	NA	NA	
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	8-9	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	10-11	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	12-14	Yes	

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed / Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL asper Annexure-II .	Yes	6-7	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	2-3	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	37-38	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	49-50	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	4-5	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provision of "Drugs Price Control Order" (wherever applicable) and the quoted rate should be at least 20% less than its MRP. In extraordinary cases the Managing Director, BMSICL has discretion to take decision. Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII .	Yes	55-56	Yes	

[Signature]
3/1/25

[Signature]
03/01/2025

[Signature]
3/1/25

[Signature]
03/01/25

12/

TENDER NO. BMSIC/DRUGS/24-13

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Unicare India Ltd. Total Number of Pages Submitted in bid documents:- 154

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	2	Acetylsalicylic acid	Aspirin Gastro-resistant Tablets IP 150 mg (page no. 127)	150 mg	Each enteric tablet contains: Aspirin IP 150 mg	10 x 14	Not mentioned	Gastro Resistant Tablet	Gastro Resistant Tablet	02.02.2017	31.12.2026	Generic	Submitted (page no. 61)
2	7	Artesunate (A) + Sulphadoxine - Pyrimethamine (B)	Anti Malarial combi Blister pack (15 years & above) (page no. 128)	Combi pack (A+B) 1 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B)	Each combi pack Blister pack contains: Antesunate Tablets 200 mg (AS) (3 Tablet) Each uncoated tablet contains: Artesunate IP 200 mg Pyrimethrine & Sulphadoxine Tablets IP (SP) (2 Tablets) Pyrimethrine IP IP 37.5 mg Sulphadoxine IP 750 mg	One Combi Blister Pack	One combi Blister pack of A- 3 Tablets + B 2 Tablets (Not as per NIT)	Tablet	Tablet	28.11.2019	31.12.2026	Generic	Submitted (page no. 62)
3	10	Dapagliflozin	Dapagliflozin Tablet (page no. 130)	10 mg	Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate Eq. to Dapagliflozin 10 mg	10 x 10	Not mentioned	Tablet	Tablet	23.07.2024 (Less than 3 year)	19.11.2028	Generic	Submitted (page no. 65)
4	12	Digoxin	Digoxin Tablets IP 0.25 mg (page no. 131)	250 mcg	Each uncoated tablet contains: Digoxin IP 0.25 mg	10 x 10	Not mentioned	Tablet	Tablet	02.02.2017	31.12.2026	Generic	Submitted (page no. 68)

37/1/25
03/01/25
3/1/25
03/01/25

120

5	14	Efavirenz	Efavirenz Tablets IP 200 mg (page no. 131 A)	200 mg	Each film coated tablet contains: Efavirenz IP 200 mg	30's Bottle	Not mentioned	Tablet	Tablet	21.01.2016	19.11.2028	Generic	MSC not submitted.
6	19	Etophylline+theophylline	Etophylline & theophylline Prolonged Release Tablets IP 150 mg (page no. 132)	115mg + 35mg	Each film coated prolonged release tablet contains: Etophylline 115 mg Theophylline anhydrous 35 mg	10 x 10's	Not mentioned	Prolonged Release Tablet	Prolonged Release Tablet	09.02.2018	19.11.2028	Generic	Submitted (page no. 70)
7	21	Glucose Powder	Dextrose Monohydrate IP 500 gm & 1000 gm (page no. 136)	Standard Composition [As per FSSAI]	Dextrose Monohydrate IP 500 gm & 1000 gm	100 gm	500 gm & 1000 gm (Not as per NIT 100 gm)	Powder	Powder	27.02.2013	Form 25 B last validity not submitted.	Generic	Submitted (page no. 72)
8	22	Glyceryl trinitrate	Nitroglycerine controlled release tablets (page no. 137)	2.6 mg	Each uncoated tablet contains: Diluted Nitroglycerine IP Eq. to Nitroglycerine 2.6 mg (In a controlled release form)	10 x 10's	Not mentioned	Tablet	Controlled Release Tablet (Not as per NIT)	21.01.2016	19.11.2028	Generic	Submitted (page no. 64)
9	24	Isosorbide Dinitrate	Isosorbide Dinitrate Tablets IP 5.0 mg (page no. 138)	5 mg	Each uncoated tablet contains: Isosorbite Dinitrate IP 5 mg (Added as Diluted Isosorbide Dinitrate IP)	10x10	Not mentioned	Sublingual Tablet	Tablet (Not as per NIT)	02.02.2017	31.12.2026	Generic	MSC not submitted.
10	25	Lamivudine (A) + Zidovudine (B)	Lamivudine & Zidovudine Tablets (page no. 139)	30 mg (A) + 60 mg (B)	Each film coated tablet contains: Lamivudine IP 30 mg Zidovudine IP 60 mg	30's Bottle	Not mentioned	Tablet	Tablet	10.08.2017	19.11.2028	Generic	MSC not submitted.





3/1/25
Jhushu
03/01/25

3/1/25

03/01/25

119

11	26	Lopinavir (A) + Ritonavir (B)	Lopinavir and Ritonavir Tablets IP (page no. 140)	100 mg (A) + 25 mg (B)	Each film coated tablets contains: Lopinavir IP 100 mg Ritonavir IP 25 mg	30's Bottle	Not mentioned	Tablet	Tablet	21.01.2016	19.11.2028	Generic	MSC not submitted.
12	29	Potassium chloride	Potassium chloride Oral Solution USP (page no. 141)	500 mg/5 ml	Each 15 ml contains: Potassium chloride IP 1.500 gm	200ml bottle	Not mentioned	Oral liquid	Oral solution	21.01.2016	19.11.2028	Generic	MSC not submitted.
13	34	Sodium Valproate	Sodium Valproate Gastro resistant tablets IP 500 mg (page no. 142)	500 mg	Each enteric coated tablet contains: Sodium valporate IP 500 mg	10 x 10	Not mentioned	Tablet	Gastro Resistant Tablet (Not as per NIT)	02.02.2017	31.12.2026	Generic	MSC not submitted.
14	38	Trifluoperazine HCL + Trihexyphenidyl HCL	Trihexyphenidyl & Trifluoperazine Tablets (page no. 143)	5 mg + 2 mg	Each uncoated tablet contains: Trihexyphenidyl Hydrochloride IP 2 mg Trifluoperazine Hydrochloride IP Eq. to Trifluoperazine 5.0 mg	10 x 10's	Not mentioned	Tablet	Tablet	02.02.2017	31.12.2026	Generic	MSC not submitted.
15	43	Zidovudine (A) + Lamivudine (B) + Nevirapine (C)	Lamivudine, Zidovudine & Nevirapine Tablets (page no. 144)	60 mg (A) + 30 mg (B) + 50 mg (C)	Each film coated tablet contains: Lamivudine IP 30 mg Zidovudine IP 60 mg Nevirapine 50 mg	60's Bottle	Not mentioned	Tablet	Tablet	10.08.2017	19.11.2028	Generic	MSC not submitted.

 3/1/25
  03/01/2025
  3/1/25
  03/01/25

18

TENDER NO. BMSIC/DRUGS/24-13

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Unicare India Ltd. Total Number of Pages Submitted in bid documents:- 154

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	2	Acetylsalicylic acid	25 (Noida)	03 of 1984	NA	NA	03.01.1984	31.12.2026	22.11.2024	21.11.2025
2	7	Artesunate (A) + Sulphadoxine - Pyrimethamine (B)	25 (Noida)	03 of 1984	NA	NA	03.01.1984	31.12.2026	22.11.2024	21.11.2025
3	10	Dapagliflozine	25 & 28 (Roorkee)	30/UA/2006 & 30/UA/SC-P/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
4	12	Digoxin	25 (Noida)	03 of 1984	NA	NA	03.01.1984	31.12.2026	22.11.2024	21.11.2025
5	14	Efavirenz	25	30/UA/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
6	19	Etophylline+theophylline	25 & 28 (Roorkee)	30/UA/2006 & 30/UA/SC-P/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
7	21	Glucose Powder	25- B	01/RPL/ of 1991	NA	NA	Form- 25 B not submitted	Last validity (26 B) not submitted	Not submitted	Not submitted





31/1/25

31/01/25

31/01/25

117

8	22	Glyceryl trinitrate	25	30/UA/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
9	24	Isosorbide Dinitrate	25 (Noida)	03 of 1984	NA	NA	03.01.1984	31.12.2026	22.11.2024	21.11.2025
10	25	Lamivudine (A) + Zidovudine (B)	25	30/UA/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
11	26	Lopinavir (A) + Ritonavir (B)	25	30/UA/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
12	29	Potassium chloride	25	30/UA/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
13	34	Sodium Valproate	25 (Noida)	03 of 1984	NA	NA	03.01.1984	31.12.2026	22.11.2024	21.11.2025
14	38	Trifluoperazine HCL + Trihexyphenidyl HCL	25 (Noida)	03 of 1984	NA	NA	03.01.1984	31.12.2026	22.11.2024	21.11.2025
15	43	Zidovudine (A) + Lamivudine (B) + Nevirapine ©	25	30/UA/2006	NA	NA	21.11.2013	19.11.2028	20.09.2024	19.09.2027
<p>Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/474-2024/9045 dt 02.01.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discreprencies are observed for rectification.</p>										

 3/1/25
 03/01/25
 3/1/25
 03/01/25

11/8